Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.

ABSTRACT:

Importance

Immune checkpoint inhibitors have been approved for use as a second-line therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib. Pembrolizumab has shown substantial antitumor activity and a favorable toxicity profile as a second-line treatment of HCC. However, considering the high cost of pembrolizumab, there is a need to assess its value by considering both the clinical efficacy and cost.

Objective

To evaluate the cost-effectiveness of pembrolizumab vs placebo as second-line therapy in patients with HCC from the US payer perspective.

Design, setting, and participants

A Markov model was developed to compare the lifetime cost and efficacy of pembrolizumab as a second-line treatment of HCC with those of placebo using outcome

SUBMITTER: Chiang CL 

PROVIDER: S-EPMC7816108 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature